New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial

Background: Helicobacter pylori eradication in penicillin-allergic patients is challenging. The effective regimen is lacking in areas with high antibiotic resistance and tetracycline unavailable. Minocycline, cefuroxime, and full-dose metronidazole are promising drugs.

Aims: To compare the eradication rate, safety, and compliance among three new bismuth quadruple therapies for first-line H. pylori eradication in penicillin-allergic patients.

Methods: This randomized trial was conducted on 450 naive patients with H. pylori infection and penicillin allergy. The 14-day minocycline-metronidazole-containing (minocycline 100 mg twice daily and metronidazole 400 mg four times/day), minocycline-cefuroxime-containing (minocycline 100 mg twice daily and cefuroxime 500 mg twice daily), and cefuroxime-metronidazole-containing (cefuroxime 500 mg twice daily and metronidazole 400 mg four times/day) bismuth quadruple therapies were randomly assigned to the participants. Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed 4-8 weeks after eradication to evaluate outcome.

Results: The differences of eradication rates in either intention-to-treat (84.0%, 82.7%, and 23 82.0%, p = .896) or per-protocol (91.7%, 90.9%, and 88.2%, p = .599) analysis among minocycline-metronidazole, minocycline-cefuroxime, and cefuroxime-metronidazole-containing bismuth quadruple therapies were statistically insignificant. The incidence of adverse events (35.1%, 22.6%, and 28.9%) and compliance (90.5%, 91.8%, and 91.9%) were similar. Taste distortion, nausea, and anorexia were more common in metronidazole-containing regimens, and dizziness was more common in minocycline-containing regimens. The allergy was rare (~3%).

Conclusions: The efficacies of three bismuth quadruple therapies containing minocycline, cefuroxime, and full-dose metronidazole (pairwise) for first-line H. pylori eradication in penicillin-allergic patients were similarly satisfactory with relatively good safety and compliance. The study was registered in the Chinese Clinical Trials Registration (ChiCTR1900023702).

Keywords: Helicobacter pylori; cefuroxime; metronidazole; minocycline; penicillin allergy; therapy.

© 2023 John Wiley & Sons Ltd.

Similar articles

Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L. Fu W, et al. Dig Dis Sci. 2017 Jun;62(6):1580-1589. doi: 10.1007/s10620-017-4564-4. Epub 2017 Apr 8. Dig Dis Sci. 2017. PMID: 28391418 Clinical Trial.

Suo B, Tian X, Zhang H, Lu H, Li C, Zhang Y, Ren X, Yao X, Zhou L, Song Z. Suo B, et al. Chin Med J (Engl). 2023 Apr 20;136(8):933-940. doi: 10.1097/CM9.0000000000002629. Epub 2023 Apr 3. Chin Med J (Engl). 2023. PMID: 37010246 Free PMC article. Clinical Trial.

Song Z, Fu W, Zhou L. Song Z, et al. BMC Gastroenterol. 2019 Jul 25;19(1):132. doi: 10.1186/s12876-019-1056-3. BMC Gastroenterol. 2019. PMID: 31345165 Free PMC article.

Mi C, Suo B, Tian X, Wang Y, Ma L, Song Z. Mi C, et al. Helicobacter. 2024 Mar-Apr;29(2):e13073. doi: 10.1111/hel.13073. Helicobacter. 2024. PMID: 38601987 Review.

Graham DY, Lee SY. Graham DY, et al. Gastroenterol Clin North Am. 2015 Sep;44(3):537-63. doi: 10.1016/j.gtc.2015.05.003. Epub 2015 Jun 19. Gastroenterol Clin North Am. 2015. PMID: 26314667 Free PMC article. Review.

Cited by

Zhou K, Li CL, Zhang H, Suo BJ, Zhang YX, Ren XL, Wang YX, Mi CM, Ma LL, Zhou LY, Tian XL, Song ZQ. Zhou K, et al. World J Gastroenterol. 2024 May 7;30(17):2354-2368. doi: 10.3748/wjg.v30.i17.2354. World J Gastroenterol. 2024. PMID: 38813048 Free PMC article.

You S, Tang X, Zhou J, Shen Y, Song X, Benghezal M, Marshall BJ, Tang H, Li H. You S, et al. Microorganisms. 2024 Feb 20;12(3):429. doi: 10.3390/microorganisms12030429. Microorganisms. 2024. PMID: 38543480 Free PMC article.

Moosazadeh Moghaddam M, Bolouri S, Golmohammadi R, Fasihi-Ramandi M, Heiat M, Mirnejad R. Moosazadeh Moghaddam M, et al. J Mater Sci Mater Med. 2023 Aug 31;34(9):44. doi: 10.1007/s10856-023-06748-w. J Mater Sci Mater Med. 2023. PMID: 37650975 Free PMC article.

Mladenova I. Mladenova I. Antibiotics (Basel). 2023 Jul 13;12(7):1184. doi: 10.3390/antibiotics12071184. Antibiotics (Basel). 2023. PMID: 37508280 Free PMC article. Review.

References

REFERENCES

    1. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724-1762.
    1. Nyssen OP, Perez-Aisa A, Tepes B, et al. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: experience from the European registry on H pylori management (hp-EuReg). Helicobacter. 2020;25(3):e12686.
    1. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-1382.e17.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30.
    1. Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64(11):1715-1720.